These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28360110)

  • 1. The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.
    Bertrand CA; Mitra S; Mishra SK; Wang X; Zhao Y; Pilewski JM; Madden DR; Frizzell RA
    Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L912-L925. PubMed ID: 28360110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR.
    Sato Y; Thomas DY; Hanrahan JW
    J Biol Chem; 2019 Nov; 294(48):18269-18284. PubMed ID: 31645438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Separating the contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia.
    Larsen MB; Choi JJ; Wang X; Myerburg MM; Frizzell RA; Bertrand CA
    Am J Physiol Lung Cell Mol Physiol; 2021 Dec; 321(6):L1147-L1160. PubMed ID: 34668421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia.
    Bertrand CA; Zhang R; Pilewski JM; Frizzell RA
    J Gen Physiol; 2009 Apr; 133(4):421-38. PubMed ID: 19289574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.
    Pinto MC; Quaresma MC; Silva IAL; Railean V; Ramalho SS; Amaral MD
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
    Kmit A; Marson FAL; Pereira SV; Vinagre AM; Leite GS; Servidoni MF; Ribeiro JD; Ribeiro AF; Bertuzzo CS; Amaral MD
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1323-1331. PubMed ID: 30716472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential contribution of SLC26A9 to Cl(-) conductance in polarized and non-polarized epithelial cells.
    Ousingsawat J; Schreiber R; Kunzelmann K
    J Cell Physiol; 2012 Jun; 227(6):2323-9. PubMed ID: 21809345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relative binding affinities of PDZ partners for CFTR: a biochemical basis for efficient endocytic recycling.
    Cushing PR; Fellows A; Villone D; Boisguérin P; Madden DR
    Biochemistry; 2008 Sep; 47(38):10084-98. PubMed ID: 18754678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecular switch in the scaffold NHERF1 enables misfolded CFTR to evade the peripheral quality control checkpoint.
    Loureiro CA; Matos AM; Dias-Alves Â; Pereira JF; Uliyakina I; Barros P; Amaral MD; Matos P
    Sci Signal; 2015 May; 8(377):ra48. PubMed ID: 25990958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of SLC26A9 in Airways and Its Potential Role in Asthma.
    Ousingsawat J; Centeio R; Schreiber R; Kunzelmann K
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slc26a9 is inhibited by the R-region of the cystic fibrosis transmembrane conductance regulator via the STAS domain.
    Chang MH; Plata C; Sindic A; Ranatunga WK; Chen AP; Zandi-Nejad K; Chan KW; Thompson J; Mount DB; Romero MF
    J Biol Chem; 2009 Oct; 284(41):28306-28318. PubMed ID: 19643730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of Cystic Fibrosis Transmembrane Conductance Regulator Function in Human Bronchial Epithelial Cells via SLC6A14-Dependent Amino Acid Uptake. Implications for Treatment of Cystic Fibrosis.
    Ahmadi S; Wu YS; Li M; Ip W; Lloyd-Kuzik A; Di Paola M; Du K; Xia S; Lew A; Bozoky Z; Forman-Kay J; Bear CE; Gonska T
    Am J Respir Cell Mol Biol; 2019 Dec; 61(6):755-764. PubMed ID: 31189070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis.
    Dougherty PG; Wellmerling JH; Koley A; Lukowski JK; Hummon AB; Cormet-Boyaka E; Pei D
    J Med Chem; 2020 Dec; 63(24):15773-15784. PubMed ID: 33314931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CFTR-Associated Ligand Arrests the Trafficking of the Mutant ΔF508 CFTR Channel in the ER Contributing to Cystic Fibrosis.
    Bergbower E; Boinot C; Sabirzhanova I; Guggino W; Cebotaru L
    Cell Physiol Biochem; 2018; 45(2):639-655. PubMed ID: 29402832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Golgi-associated PDZ domain protein modulates cystic fibrosis transmembrane regulator plasma membrane expression.
    Cheng J; Moyer BD; Milewski M; Loffing J; Ikeda M; Mickle JE; Cutting GR; Li M; Stanton BA; Guggino WB
    J Biol Chem; 2002 Feb; 277(5):3520-9. PubMed ID: 11707463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.
    Strug LJ; Gonska T; He G; Keenan K; Ip W; Boëlle PY; Lin F; Panjwani N; Gong J; Li W; Soave D; Xiao B; Tullis E; Rabin H; Parkins MD; Price A; Zuberbuhler PC; Corvol H; Ratjen F; Sun L; Bear CE; Rommens JM
    Hum Mol Genet; 2016 Oct; 25(20):4590-4600. PubMed ID: 28171547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubiquitination and degradation of CFTR by the E3 ubiquitin ligase MARCH2 through its association with adaptor proteins CAL and STX6.
    Cheng J; Guggino W
    PLoS One; 2013; 8(6):e68001. PubMed ID: 23818989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
    Yu W; Kim Chiaw P; Bear CE
    J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
    Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
    Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CAL as a negative regulator of DeltaF508-CFTR cell-surface expression: an RNA interference and structure-based mutagenetic approach.
    Wolde M; Fellows A; Cheng J; Kivenson A; Coutermarsh B; Talebian L; Karlson K; Piserchio A; Mierke DF; Stanton BA; Guggino WB; Madden DR
    J Biol Chem; 2007 Mar; 282(11):8099-109. PubMed ID: 17158866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.